Leukemia News

Hematopoietic stem cell transplant recipients of non-European ancestry had a significantly higher likelihood of receiving allogeneic grafts from HLA-mismatched donors than individuals of European ancestry, study results showed.

Higher allostatic load, a measure of lifelong stress, correlated with increased risk for cancer mortality, especially among younger populations, according to study results published in SSM Population Health.

Patient navigation programs have historically been difficult to implement on a large scale.

The FDA approved olutasidenib for treatment of certain adults with relapsed or refractory acute myeloid leukemia.

Maintenance therapy with eprenetapopt plus azacitidine after hematopoietic stem cell transplantation led to improved survival outcomes among patients with TP53-mutant acute myeloid leukemia or myelodysplastic syndrome, study results showed.

A dramatic rise in global incidence of early-onset cancers over the past 30 years may be related in part to increased exposure to risk factors at a young age, according to study results published in Nature Reviews Clinical Oncology,

Eyal Gottlieb, PhD, has been named vice president for research at The University of Texas MD Anderson Cancer Center.

For the second time in the last 2 years, a drug related to the administration of cellular therapy — fludarabine — has been placed on the FDA’s drug shortage list.

The addition of ponatinib to chemotherapy increased the minimal residual disease-negative complete remission rate for certain adults with acute lymphoblastic leukemia, according to the agent’s manufacturer.

Despite data on the approach still being accumulated, a panel of experts at Chemotherapy Foundation Symposium predicted that chimeric antigen receptor T cells will become front-line therapy for multiple hematologic malignancies.